Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Smartphone detects parasites in the blood
Cellscope
The device works by filming a pinprick of blood and analysing movement to predict the number of L. loa parasites present.

Device may allow disease eradication programs to resume

A smartphone has been used to detect the 'wriggling' motion of parasites in the blood. The rapid test could allow suspended disease eradication programmes in Central Africa to resume.

Attempts to eliminate two parasitic diseases - onchocerciasis (or river blindness) and lymphatic filariasis (LF) - have been put on hold as the anti-parasitic treatment, Ivermectin (IVM), can cause serious adverse effects, even death, in patients who also have high levels of the Loa loa parasite.

Small trials of the CellScope system in Cameroon have proved successful, scientists report in the journal Science Translational Medicine.

The device works by filming a pinprick of blood and analysing movement to predict the number of L. loa parasites present in the sample. This allows healthcare workers to decide whether the patient can be safely treated with IVM.

These findings could facilitate a proposal to 'test and (not) treat)', whereby patients are screened prior to treatment with IVM, and those with high levels of L. loa microfilariae are excluded from the mass drug administration program.

For this proposal to be put into place, a rapid and inexpensive test is needed that can be used at point of care.

Current manual counts require trained healthcare workers and laboratory equipment, however, the CellScope system can provide results in minutes and workers do not need substantial training in order to use it.

L. loa is highly endemic in Central Africa. Diseases such as river blindness, LF and loiasis are the cause of major public health and socioeconomic problems in Africa's co-endemic regions. River blindness is the second most common cause of infectious blindness in the world, while LF infects 120 million people across the globe and is the second leading cause of disability.

Writing in Science Translational Medicine, researchers said: "The device reported here provides an example of how mobile phone technology can be used to address critical gaps in the treatment of neglected tropical diseases."

Researchers hope the device could also be developed for use in detecting other infections.

 

Image courtesy of Prof Daniel Fletcher

Become a member or log in to add this story to your CPD history

RUMA CA&E extends survey deadline

News Story 1
 RUMA CA&E has extended the deadline for its online survey into vaccine availability.

Vets, SQPs, retailers and wholesalers will now have until Friday, 26 September at 5pm to submit their response.

The survey aims to further understanding into the vaccine supply challenges faced by the sector. It will also consider the short and long term impacts of disruption issues.

Insights are anonymous, and will be shared with industry stakeholders and government bodies.

The survey can be accessed here

Click here for more...
News Shorts
Dechra launches checklist for veterinary sustainability

Global animal health specialist Dechra has announced the world's first Veterinary Green Theatre Checklist (VGTC) to help make surgery more sustainable.

Endorsed by leading veterinary organisations, including the BEVA, BVNA and RCVS Knowledge, the checklist is designed to reduce the environmental footprint of veterinary care, while supporting better animal health outcomes.

The checklist was launched at the World Congress of Veterinary Anaesthesia and Analgesia in Paris and will be followed by an internal training and awareness campaign. For more information, visit dechra.com